Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
4(36%)
Results Posted
100%(4 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_1
3
27%
Ph not_applicable
2
18%
Ph phase_2
5
45%

Phase Distribution

3

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
3(30.0%)
Phase 2Efficacy & side effects
5(50.0%)
N/ANon-phased studies
2(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

4

trials recruiting

Total Trials

11

all time

Status Distribution
Active(4)
Completed(4)
Terminated(3)

Detailed Status

Completed4
Active, not recruiting3
Terminated2
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
4
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (30.0%)
Phase 25 (50.0%)
N/A2 (20.0%)

Trials by Status

active_not_recruiting327%
completed436%
terminated218%
recruiting19%
withdrawn19%

Recent Activity

4 active trials
Showing 5 of 11
active_not_recruitingphase_1

CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

NCT03572764
active_not_recruitingphase_2

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

NCT04331041
active_not_recruitingphase_1

Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma

NCT03921008
completedphase_2

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

NCT03449901
recruiting

Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG

NCT05672615
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT03572764Phase 1

CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

Active Not Recruiting
NCT04331041Phase 2

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Active Not Recruiting
NCT03921008Phase 1

Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma

Active Not Recruiting
NCT03449901Phase 2

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

Completed
NCT05672615

Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG

Recruiting
NCT05265715Not Applicable

A Low AGE (Advanced Glycation End-product) Dietary Intervention for Breast Cancer Survivors

Completed
NCT04536077Phase 2

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Terminated
NCT04553471Not Applicable

Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers

Completed
NCT03007979Phase 2

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Completed
NCT03422094Phase 1

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Terminated
NCT03598816Phase 2

PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma

Withdrawn

All 11 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
11